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Background: Oncogenic HPV infection is associated to anogenital cancer. We estimate the prevalence and
correlates of anogenital HPV infection among a population-based sample of women aged 16–64 years
living in the metropolitan area of Puerto Rico.
Methods: 564 women completed face-to-face and computer assisted interviews and self-collected anal
and cervical specimens. HPV DNA testing used MY09/MY11 consensus HPV L1 primers and beta-globin as
an internal control for sample ampliﬁcation. Positive specimens were typed by dot-blot hybridization.
Results: Weighted prevalence of cervical, anal, and cervical/anal co-infection was 29.4%, 38.6%, and 17.1%,
respectively. The commonest oncogenic HPV types detected in the cervix and anus were: 68 (8% vs. 7%)
and 16 (5.5% vs. 5.1%), correspondingly. Having Z3 lifetime sexual partners (OR: 2.3; 95% CI: 1.5–3.5) and
last year anal intercourse (OR: 1.6; 95% CI: 1.1–2.5) increased the odds of anogenital HPV infection.
Cervical infection was independently associated to anal infection (OR: 3.0; 95% CI: 2.0–4.6).
Conclusions: Similar to others, our results conﬁrm the burden of anogenital HPV infection in women and
its relationship with sexual behavior. As vaccination increases, future studies should monitor changing
trends in HPV infection in this population, and the relationship between anal and cervical HPV-related
disease.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Human papillomavirus (HPV) is mainly transmitted through
sexual contact and it is common among the general population [1].
HPV genotypes are classiﬁed as High Risk (HR) or Low Risk (LR)
types depending on their oncogenic potential, HR infections cause
cervical and anal cancers [1–3]. The cervix and anus possess a
transformation zone characterized by a metaplastic epithelial site,
which make them susceptible for HPV infection [3]. HPV pre-
valence differs across geographical regions and depends on age
distribution and sexual practices of the populations [4,5]. Despite
the burden of HPV infection and its causal relationship with var-
ious cancers [1–3], there is no routine surveillance system for HPV.access article under the CC BY-NC
prehensive Cancer Center &
te School of Public Health, POAlthough HPV-16 is the most common HPV genotype at the
time of cervical diagnosis of squamous cell carcinoma (SCC), HPV-
18 is the type most strongly associated with adenocarcinoma [2].
Three vaccines have been licensed for the prevention of HPV in-
fection and its related malignancies [6]. In order to assess the
impact of HPV vaccination programs, it is essential to establish
baseline estimates of the type-speciﬁc HPV prevalence in the
general population [7–9].
Our group has documented a high burden of HPV-related
cancers in Puerto Rico [10–13], as well as an elevated prevalence of
high-risk sexual practices [14]. Having baseline information on the
burden of cervical and anal HPV infections is important in order to
measure the impact in the prevention and control of HPV infection
and related malignancies in this population, which still has low
vaccine uptake [15]. This study described the prevalence and
correlates of cervical and anal HPV infections in a population-
based sample of women living in the San Juan Metropolitan area
(SJMA) of Puerto Rico.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A.P. Ortiz et al. / Papillomavirus Research 2 (2016) 89–96902. Methods
2.1. Study population
A detailed description of the design and methods of this study
has been described elsewhere [16]. Brieﬂy, 566 non-in-
stitutionalized women aged 16–64 years living in the SJMA of
Puerto Rico participated in the study from August 2010 to May
2013. Participants were identiﬁed through a four-stage probability
sample design of households in the SJMA: stage-1) systematic
random selection of 50 census blocks groups; stage-2) random
selection of one block from each census block group; stage-3)
random selection of one segment of about 12–16 households on
each census block was randomly selected; and stage-4) selection
of one eligible woman per household. If more than one woman
were eligible, selection was performed by simple random sam-
pling. Women were not eligible to participate if they were HIV
positive, pregnant, and/or were cognitive or physically impaired.
All 566 participants signed the informed consent and completed
study procedures. Of these, 564 provided adequate cervical and
anal samples for HPV testing. All cervical specimens (100%) and
95% of anal specimens (n¼536) were positive for the human β-
globin, and thus suitable for HPV typing [16]. This study was ap-
proved by the Institutional Review Board of the Medical Sciences
Campus, University of Puerto Rico.
2.2. Data collection procedures
After signing the informed consent, women completed a face-
to-face interview and a self-administered questionnaire using an
Audio Computer Assisted Self-Interview (ACASI) system. The face-
to-face interview collected information on risk factors for ano-
genital HPV infection, including demographic and behavioral
characteristics and reproductive and health history. The ACASI
system was used to collect sensitive information on sexual prac-
tices, condom utilization, and drug use.
2.3. Biological specimens' collection
Anal and cervical specimens were self-collected. Each partici-
pant received a collection kit that included the necessary materials
for self-collection. Additionally, staff personnel provided a verbal
explanation and written instructions including diagrams, com-
parable to those used in past studies [17,18], to each participant.
Upon completion of the study procedures, samples were stored at
70 °C and shipped on dry ice to the University of California, San
Francisco for HPV typing. After completing the study procedures,
participants received educational material on HPV and HPV vac-
cine, and a monetary compensation for their time and effort.
2.4. Analysis of cervical and anal biological specimens
HPV DNA was puriﬁed from samples. HPV typing was per-
formed using L1 consensus primer polymerase chain reaction
(PCR) with MY09/MY11 primers sets and β-globin as an internal
control for sample ampliﬁcation. PCR products from positive
samples were typed by dot-blot hybridization using 40 individual
type-speciﬁc probes, including oncogenic HR HPV types as deﬁned
by the International Agency of Research on Cancer (IARC) (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) and non-oncogenic
types LR (6/11, 26/69, 30, 32/42, 34, 53, 54, 57/2/27, 61, 62, 66, 67,
70, 71, 72, 73, 81, 82, 83, 84, 85, 86/87, 90/106, 97, 102/108, as well
as 2 separate mixtures, mix1 contains 7/13/40/43/44/55/74/91, and
mix2 contains 3/10/28/29/77/78/94 plus all those HPV types that
hybridized only with the consensus probe). Samples that were
positive for the consensus probe on the Linear Array (LA) HPV stripwere considered HPV positive and those that were negative for the
consensus probe were considered HPV negative. Specimens with
β-globin undetected were considered inadequate and were ex-
cluded from the analysis.
2.5. Statistical analysis
The variables cervical infection (yes/no) and anal infection (yes/
no) were deﬁned independently. In addition, participants were
classiﬁed into one of four groups according to their cervical–anal
HPV infection status: (1) no HPV infection in either site (Cervix/
Anus), (2) HPV infection only in the anus (Cervix/Anusþ),
(3) HPV infection only in the cervix (Cervixþ/Anus), and (4) HPV
concurrent cervical/anal infection or co-infection (Cervixþ/An-
usþ). The overall and type-speciﬁc HPV prevalence, for each group
above, was estimated with 95% conﬁdence intervals (95% CI) using
a logistic regression model. In order to control for the effect of the
sampling design on the prevalence estimation, a normalized
weighting factor was considered in this model using the inverse
probability of selection for each participant and the inverse
probability of participation [16] as follows:
= ( × )¯w
f f
w
1/
i
1 2
where f1 indicates the selection probability for each participant, f2
is the rate of participation in each block, and w¯ is the mean ﬁnal
weight of the entire sample.
Meanwhile, the Kappa statistic was used to assess the con-
cordance of the HPV types observed in the cervical and anal
samples among women with co-infection. The chi-square statistic
was used to assess differences in covariates across the four groups
and an age-adjusted polytomous logistic regression model was
used to quantify the magnitude of the association between cer-
vical–anal HPV infection categories and covariates. Given the small
sample size in each category, and thus limited statistical power for
detecting differences in the groups HPV positive in different ana-
tomical sites, a multivariate logistic regression model (MLRM) was
also used to describe factors associated to any anogenital HPV
infection, using those cervix/anus as the reference group.
Furthermore, in order to assess the association between anal and
cervical infection, another multivariate logistic regression model,
adjusted by covariates signiﬁcantly associated in the bivariate
analysis to anal and cervical infection, was used. Variables that
were signiﬁcant (po0.05) in the bivariate analyses to the outcome
variables for each case and those considered relevant based on the
previous literature were included in the polytomous and MLRMs
models to estimate the adjusted odds ratio (OR). The MLRMs were
ﬁtted using an estimable generalized equations approach for
controlling the correlation between the measurements of women
living in the same households block. Evaluation of interaction
terms in these models was performed using the likelihood ratio
test. The statistical package Stata (Version 13.0, College Station, TX,
USA) was used to perform data management and all statistical
analyses.3. Results
3.1. Weighted HPV prevalence by anatomic site
The prevalence of cervical HPV infection (29.4%, 95% CI: 23.2–
36.4%) was lower than anal HPV infection (38.6%, 95% CI: 30.1–
47.9%). The prevalence of HR types in the cervix (8.4%, 95% CI: 5.6–
12.6%) was lower than LR types (17.4%, 95% CI: 13.0–23.0%), while
anal prevalence for HR and LR types was similar (12.5%, 95% CI:
8.4–18.3% and 12.3%, 95% CI: 8.7–17.3%, respectively). Meanwhile,
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A.P. Ortiz et al. / Papillomavirus Research 2 (2016) 89–96 91the weighted prevalence of HPV co-infection was 17.1% (95% CI:
12.6–22.8%), co-infection of HR types was 4.2% (95% CI: 2.1–8.2%)
and of LR types was 6.4% (95% CI: 3.9–10.4%) (Table 1).
3.2. Distribution and concordance of HPV types
Among HPV infected women, 7% of cervical specimens and 15%
of anal specimens were untyped. The commonest oncogenic HPV
types detected in the cervix and anus were: 68 (8% vs. 7%) and 16
(5.5% vs. 5.1%), followed by 58 (4.5%) and 31 (3.5%) in the cervix
and 51 (5.1%) and 18 (4.2%) in anus (Fig. 1). Among women with
cervical and anal HPV co-infection (n¼112), the highest pre-
valence of co-infection with HR types was for HPV 16 (4.5%), fol-
lowed by 51 (2.7%) and 68 (2.7%); only 1.8% of women were co-
infected with type 18. Meanwhile, for LR types, the highest pre-
valence of co-infection was for HPV 61 (4.5%), followed by HPV 62,
81, 82 and 83, all with 2.7%; only 0.9% was co-infected with HPV 6/
11. Meanwhile, a high agreement percent (487%) was observed
for each of the speciﬁc HPV types for which co-infection was de-
tected (HR types: 16, 18, 51, 52, 56, 59 and 68, and LR types: 6/11,
32/42, 53, 54, 61, 62, 71, 72, 81, 82, 83, and Mix 1). Kappa estimates
showed a marginal to good concordance (68: k¼0.36, 16: k¼0.56,
and 51: k¼0.47) for the most prevalent types in co-infected wo-
men; it was highest for HPV 82 (k¼0.58) and 83 (k¼0.65) (Data
not shown).
3.3. Factors associated to anogenital HPV infection site
Among women with complete information on cervical and anal
HPV infection status (n¼536), 47% of them were negative to HPV
in both anatomical sites, 21% were positive in both sites, 19% had
only anal HPV infection, and 13% had cervical infection alone.
Prevalence of HPV co-infection decreased with increasing age
(Supplementary Table 1 and Fig. 2); womenwith co-infection were
more likely to be younger (aged 16–34, 55%), had a lower annual
family income (o$20,000, 70%), had 3 or more lifetime sexual
partners (87%), and were more likely to report current drug use
(23%). Women with anal infection alone were more likely to have
had anal sex in the last year (44%) and women with cervical in-
fection alone reported to be current smokers (25%) (Supplemen-
tary Table 1).
The age-adjusted polytomous logistic regression model showed
signiﬁcant differences (po0.05) in the following characteristics:
anogenital HPV infection status by age, education, marital status,
health care coverage, age of sexual debut, lifetime number of
sexual partners, last year anal sex, smoking and drug use (Table 2).
Meanwhile, the fully adjusted multivariate logistic regression
model showed that single women (adjusted odds ratio [ORadj]¼1.7,
95% CI: 1.0–2.7) and those divorced, separated or widowed
(ORadj¼1.9, 95% CI: 1.2–3.1) were more likely to have anogenital
HPV infection as compared to married women. In addition, the
likelihood of HPV infection increased in women having 3 or more
lifetime sexual partners (ORadj¼2.3, 95% CI: 1.5–3.5) and among
women who had performed anal sex in the past 12 months
(ORadj¼1.6, 95% CI: 1.1–2.5) (Table 2). Regarding the relationship
between cervical and anal HPV infection, the covariate fully-ad-
justed logistic regression model showed that women with cervical
HPV infection were more likely to have anal HPV infection (ORadj:
3.0; 95% CI: 2.0–4.6) than those without cervical HPV infection,
after adjustment by age, education, marital status, health care
coverage, age of sexual debut, lifetime number of sexual partners,
last year anal sex and drug use (po0.001; data not shown).
4. Discussion
This is the ﬁrst study to describe the prevalence of anogenital
Fig. 1. Prevalence of HPV genotypes among positive women for each anatomical site.
Fig. 2. Anogenital HPV infection by age group (n¼536).
Note: p-values for trend: anusþ/cervix-¼40.10; anus-/cervixþ¼40.10; anusþ/
cervixþ¼o0.001.
A.P. Ortiz et al. / Papillomavirus Research 2 (2016) 89–9692HPV infection and the distribution of HPV genotypes among a
population-based sample of Hispanic women living in Puerto Rico.
Study results are of impact to this population, as they serve as
baseline information on the burden of cervical and anal HPV in-
fections, and will thus serve to monitor the impact of HPV vacci-
nation in this population, as has been done in the USA with
NHANES data [19]. Our results and their comparisons with other
populations are summarized in Table 3. Overall, the prevalence of
cervical HPV infection observed in our study in Puerto Rico (29.4%)
was below the prevalence reported in the USA (NHANES, 2007–
2010) among women aged 18–59 years (42%) [20]. Our estimate,
when restricting the analysis to the 18–34 age group (48%, n¼174,
data not shown), was similar to that reported in a clinic-based
sample of women in that age group in Puerto Rico [17].Meanwhile, our prevalence of cervical HPV infection is consistent
with prior reports [21–23], although higher than others [24,25]
(Table 3). Our results also showed a higher overall prevalence of LR
HPV infection (17%) than HR infection (8%) in the cervix, similar to
other studies [21,22], but contrary to others [23,24]. Regarding
prevalence of anal HPV infection, our estimate (39%) is higher than
that described in other reports [23,25,26], although similar pre-
valence was observed when compared to the clinic-based study in
Puerto Rico, when restricting the analysis to the same age group
(52%, n¼166, data not shown) [17]. Nonetheless, contrary to the
cervix, the overall prevalence of HR and LR infections was similar
in the anus (12%); the Hawaiian study reported an overall higher
LR than HR infection [23]. It is important the future studies try to
assess the reasons for the differences in HPV prevalence between
the anus and the cervix, including the reasons for the differences
in HR vs. LR types in different anatomical sites. For example, in
cervix, HPV infection has been associated to vaginal pH and spe-
ciﬁc vaginal microbiota [27–29], thus, differences in vaginal and
anal microbiota could also account for these differences; more
research is warranted in this area.
Among other comparisons, the prevalence in our study of HPV
co-infection (cervix and anus), and of infection only in the anus,
were higher than the one reported in Hawaii (21% vs. 13% and 19%
vs. 14%, respectively), although cervical infection alone was similar
in both studies (13% vs. 14%) [23]. The prevalence of co-infection of
younger women from Costa Rica (20%) was similar to ours, but
they reported a lower prevalence of anal infection than cervical
infection [26], contrary to our ﬁnding. These differences could be
the result of the high prevalence of lifetime anal sex reported in
our population (70%) vs. the low practice of this behavior in Ha-
waii (21%) and Costa Rica (21%) [23,26]. American Samoa reported
Table 2
Age-adjusted associations of cervical–anal HPV infection status with demographic, sexual, and lifestyle characteristics and magnitude of the association between anogenital
infection and different variables.
Variables Age-adjusted polytomous regression modelsa (n¼536) Multivariate logistic regression modelb
(n¼564)
Reference (Cervix-/
Anus-)
Cervix-/Anusþ ORa
(95% CI)
Cervixþ/Anus- ORa
(95% CI)
Cervixþ/Anusþ ORa
(95% CI)
Any Anogenital Infection ORb (95% CI)
Age
16–34 1.0 1.0
35–49 0.9 (0.5–1.6) 0.8 (0.4–1.6) 0.3 (0.2–0.5)† 0.7 (0.4–1.1)
50–64 0.7 (0.4–1.3) 0.72 (0.4–1.4) 0.2 (0.1–0.4)† 0.7 (0.4–1.2)
Education
Z12 years 1.0 1.0
o12 years 1.8 (1.0-3.4)‡ 1.6 (0.7–3.3) 2.5 (1.4–4.6)† 1.3 (0.7–2.3)
Marital status
Married/LT 1.0 1.0
Div/Sep/widow 2.3 (1.3–4.1)† 4.5 (2.3–8.7)† 3.2 (1.7-6.1)† 1.9 (1.2–3.1)†
Single 1.2 (0.6–2.3) 2.3 (1.1–4.8)† 2.5 (1.4–4.5)† 1.7 (1.0–2.7)†
Health care coverage
Private 1.0 1.0
Public 1.8 (1.1–3.0)† 2.1 (1.2–3.8)† 1.9 (1.2–3.1)† 1.5 (1.0–2.3)‡
None 1.2 (0.5–2.8) 2.2 (1.0–5.2)‡ 0.9 (0.4–2.2) 1.1 (0.6–2.0)
Age of sexual debut
Z15 years 1.0 1.0
o15 years 1.7 (0.8–3.3) 1.2 (0.5–2.9) 2.2 (1.2–4.1)† 1.1 (0.6–1.9)
Lifetime sexual partners
1–2 1.0 1.0
Z3 2.5 (1.5–4.3)† 1.9 (1.1–3.4)† 4.5 (2.4–8.3)† 2.3 (1.5–3.5)†
Last year anal intercourse
No 1.0 1.0
Yes 2.2 (1.3–3.7)† 1.3 (0.7–2.4) 1.5 (0.9–2.4) 1.6 (1.1–2.5)†
Current drug user
No 1.0 1.0
Yes 1.4 (0.7–2.9) 1. (0.6–3.2) 2.0 (1.1–3.8)† 1.3 (0.7–2.3)
Current smoking
No – 1.0
Yes 1.6 (0.9–3.0) 2.2 (1.1–4.1)† 1.6 (0.9–3.0) 0.8 (0.5–1.4)
Current drinking
No – 1.0
Yes 1.0 (0.6–1.6) 1.4 (0.8–2.4) 1.6 (0.9-2.6)‡ 1.1 (0.7–1.6)
Lifetime same sex partner
No – 1.0
Yes 1.7 (0.7–4.2) 1.2 (0.4–3.7) 2.3 (1.0–5.3)‡ 1.5 (0.7–3.2)
† po0.05.
‡ 0.05opo0.1.
a The age-adjusted Odds Ratio were estimated by a polytomous logistic regression model having women without infection as the reference category, analysis was
performed among women with paired anal and cervical samples.
b The Odds Ratio was adjusted by all risk factors presented in the above MLRM column.
A.P. Ortiz et al. / Papillomavirus Research 2 (2016) 89–96 93the lowest HPV co-infection rate (4%); however, this study did not
include information on anal sexual behavior, because it was con-
sidered sensitive by the community members [25]. However, they
report traditional cultural lifestyles and lower risk sexual practices,
including higher age of sexual debut (20.5 years) [25]. We re-
cognize that these and other comparisons with other populations
need to be made with caution, as differences in study period, age
of study groups, method for obtaining HPV samples, anddifferences in HPV assays' methodology (HPV assays' sensitivity
and detection estimates are inﬂuenced by differences in meth-
odologies used: e.g.; method for genotyping, DNA puriﬁcation
method, PCR primers, and ampliﬁcation techniques) might par-
tially explain these variations.
With respect to the prevalence of speciﬁc HPV types, two of the
commonest HPV HR genotypes found in our cervical samples (16
and 58) were also two of the most prevalent types reported in
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A.P. Ortiz et al. / Papillomavirus Research 2 (2016) 89–9694Costa Rica [21], and Colombia [24], consistent with the most
common types described in Central and South America in women
with normal cytology [4]. HPV genotype 16 was also one of the
commonest found among women in other studies [20,22,23], but
our most prevalent HR type, 68, was not as common in other
populations. Similarly to our results in cervix, two of the com-
monest HR HPV types in our anal samples (16 and 51) were also
common in Costa Rica [26]. It is important to highlight that in both
anatomical sites, we found HPV types that are included in the
three currently available HPV vaccines: Cervarix (HPV 16 and 18),
Gardasil (HPV 6, 11, 16 and 18) and Gardasil 9 (6, 11, 16, 18, 31, 33,
45, 52 and 58). Nonetheless, HPV 68, our most common, is not
currently included in any HPV vaccine. Although studies in other
populations have found that HPV 16 and 18, and not 68, are found
in most cervical and anal cancers [30], it is yet to be evaluated if
the same is the case for Puerto Rico, and if these are the strongest
types associated with cancer development in this population. Re-
sults of the most common HPV types identiﬁed in this population-
based sample of women in Puerto Rico will help future studies
determine if changes in the distribution of HPV types occur in this
population with increasing uptake of HPV vaccination, as has been
documented in young women in the USA [19].
Although both the cervix and anus shared the commonest
oncogenic HPV types, the concordance evaluation in co-infected
women showed a marginal to good concordance in the most
prevalent types, which is similar to kappa values reported in a
previous study carried in a clinical setting in Puerto Rico in self-
collected samples (HPV 68 kappa: 0.38, 16 kappa: 0.52 and 51
kappa: 0.42) [17]. Since no information about previous infection of
the same genotype in the alternate anatomical site is available due
to the non-longitudinal nature of this study, no evidence of a
common source or route of transmission could be established.
Similar ﬁndings of the replication of the commonest genotypes in
both anatomical sites were documented in a Belgium study, in
their case with respect to HPV 16, 51, and 39 [31]. Meanwhile, we
found a three-fold association between cervical and anal infection,
which is consistent with Hawaiian [23] and American Samoa [25]
results. Thus, the coexistence and association of anal and cervical
HPV infections and the high frequency of the same genotypes on
both anatomical sites evidences that both sites could share a si-
milar risk of infection and may suggest a possible transmission
between both sites [23,31,32]. This association also supports the
biologic plausibility of the increased risk of anal cancer docu-
mented among women with gynecologic cancers [33]. None-
theless, longitudinal studies are warranted in this population to
further understand the mechanisms of HPV transmission and
persistence in the anogenital area. Meanwhile, the relative high
prevalence of HPV 16 in both anatomical sites could be explained
by its lower clearance rate compared to other oncogenic HPV types
[32,34] and by the clearance delay caused by the high frequency of
anal sex intercourse, practiced in our study group [35].
Our results also support previous ﬁndings reported in Hawaii
[23], such as the inverse association between age and HPV co-in-
fection, but not with anal infection. The high prevalence of HPV
co-infection at younger ages could be associated to riskier sexual
behaviors in younger cohorts, as previously evidenced in Puerto
Rico [14]. Conversely, we did not observe an inverse association
between age and cervical infection alone as was observed in Ha-
waii [23]. The strongest risk factor for anogenital HPV infection in
our study was increased number of lifetime sexual partners (Z3),
which is consistent with ﬁndings reported in Hawaii [23] and in
other populations [20,23–26]. This ﬁnding is aligned with data
from the IARC, which evidences that the number of sexual part-
ners is the main determinant of anogenital HPV infection [30].
Meanwhile, although previous ﬁndings have documented the as-
sociation of younger age of sexual debut with increased HPV
A.P. Ortiz et al. / Papillomavirus Research 2 (2016) 89–96 95prevalence in some [20,23], but not all studies [21,24]; this factor
was only associated with co-infection in our study. Meanwhile, the
association observed in our study between anogenital HPV infec-
tion and anal sexual intercourse in the last year evidences the
relevance of anal intercourse in the risk of anal cancer develop-
ment [36]; HR types have been detected in more than 80% anal
cancer cases [30]. Furthermore, research has reported lower con-
dom utilization during anal intercourse than during vaginal in-
tercourse, which increased the risk of STD's in women [37].
4.1. Strengths and limitations
Among strengths, a previously validated self-collection meth-
odology that showed good to excellent agreement between phy-
sician and self-collected samples was employed in our study
[17,38], supporting the feasibility of using cervical and anal self-
sampling methods in population-based studies. Likewise, the high
response rate (99.6%) of women providing anal and cervical self-
collected specimens represented a study's strength. As well, ac-
curate prevalence HPV results were obtained from our population-
based study, eliminating bias of testing performed on gynecolo-
gical clinics, which could probably inﬂate HPV prevalence due to
possible gynecological symptoms. However, our ﬁndings might
not be generalizable to the entire Puerto Rican women population
aged 16–64 years as the study sample was selected only from the
San Juan Metropolitan area. In addition, concordance results
among co-infected women (cervix and anus) should be taken with
caution since the kappa statistic is affected by low prevalence, as it
is the case for most of the genotypes evaluated.5. Conclusions
As also observed world-wide, this study evidences that ano-
genital HPV infection in women from the San Juan Metropolitan
area of Puerto Rico is common, and that for the most part, the
greatest prevalent genotypes coincide with those reported in other
populations. Our results are also consistent with previous studies
conﬁrming the relevance of sexual behavior in the risk for ano-
genital HPV infection and the strong association between cervical
and anal HPV infection. Future studies should continue monitoring
changing trends in HPV infection (including genotypes) in this
population, and the relationship between anal and cervical HPV-
related disease. Public health efforts should continue to focus on
strengthening strategies for HPV-related cancer prevention for
women and men in this population. These strategies should pro-
mote population awareness of HPV transmission and safer sexual
behaviors, along with information about their impact on anogen-
ital cancers. Educational intervention efforts should focus on the
beneﬁts of HPV vaccination and Pap test use combined with HR
HPV screening, as the key for cancer prevention in this area.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.pvr.2016.04.002.References
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